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Developing a blood-based 
gene mutation assay as a novel 
biomarker for oesophageal 
adenocarcinoma
Hasan N. Haboubi1, Rachel L. Lawrence1, Benjamin Rees1, Lisa Williams2, James M. Manson3, 
Neam Al-Mossawi4, owen Bodger  5, paul Griffiths6, Catherine thornton  7 & 
Gareth J. Jenkins  1
the phosphatidylinositol glycan class A (PIG-A) gene mutation assay phenotypically measures 
erythrocyte mutations, assessed here for their correlation to neoplastic progression in the gastro-
oesophageal reflux disease (GORD)-Barrett’s metaplasia (BM)-oesophageal adenocarcinoma (OAC) 
model. Endoscopy patients underwent venipuncture and erythrocytes fluorescently stained for glycosyl 
phosphatidylinositol (GPI)–anchored proteins; CD55 and CD59. Using flow cytometry, GPI–anchor 
negative erythrocytes (mutants) were scored and compared amongst groups. The study enlisted 200 
patients and 137 healthy volunteers. OAC patients had a three–fold increase in erythrocyte mutant 
frequency (EMF) compared to GORD patients (p < 0.001) and healthy volunteers (p < 0.001). In OAC 
patients, higher eMF was associated with worsening tumour staging (p = 0.014), nodal involvement 
(p = 0.019) and metastatic disease (p = 0.008). Chemotherapy patients demonstrated EMF’s over 
19–times higher than GORD patients. Patients were further classified into groups containing those 
with non-neoplastic disease and those with high-grade dysplasia/cancer with 72.1% of cases correctly 
classified by high EMF. Within the non-neoplastic group, aspirin users had lower EMF (p = 0.001) and 
there was a positive correlation between body mass index (p = 0.03) and age (p < 0.001) and EMF. 
Smokers had EMF’s over double that of non-smokers (p = 0.011). Results suggest this test could help 
detect oAC and may be a useful predictor of disease progression.
Barrett’s oesophagus is a premalignant condition caused by the transformation of the normal squamous mucosa 
of the lower oesophagus to columnar-type mucosa. This is caused by chronic exposure to refluxate constituents 
in patients with gastro-oesophageal reflux disease (GORD)1. GORD affects between 10–30% of the population 
and 10% of these individuals will develop Barrett’s metaplasia (BM)2. The subsequent risk of non-dysplastic BM 
patients developing oesophageal adenocarcinoma (OAC) is approximately 0.33% per year3. The rate of increase 
of OAC has risen by 600% in recent decades4 and has one of the worst five-year survival rates of any cancer due 
to the late presentation of symptoms5. It is recognized that early detection is vital in this cancer type and so sur-
veillance programmes based on the premalignant Barrett’s metaplasia diagnosis are widespread. Conventional 
surveillance of patients with Barrett’s in the UK is through 2 yearly endoscopies with biopsies6, but this still fails to 
identify over 50% of patients with asymptomatic GORD who never undergo endoscopy, but later develop cancer7.
Dysplasia has been the longstanding benchmark used in stratifying disease and assessing the risk of pro-
gression to cancer in Barrett’s patients8 but requires expert gastrointestinal-pathology input and there is clear 
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inter-observer variation9. Biomarker research aimed at complementing histological assessment shows prom-
ise, however such biomarkers require endoscopy to visualize the oesophageal mucosa and/or retrieve biopsies 
for histological evaluation. Thus, the development of less invasive biomarkers of cancer risk would clearly be 
advantageous.
Although, the recently developed Cytosponge has the potential to monitor OAC development through pri-
mary care on a large epidemiological scale10, blood-based techniques have also received attention in other cancer 
types.
There have been exciting developments recently highlighting the use of blood tests for the detection of early 
cancers and the monitoring of cancer recurrence and response to therapy. These blood tests offer the hope of 
minimally invasive approaches that could be deployed in various clinical settings to improve early detection capa-
bilities. This has even been suggested to offer the possibilities of future population wide screening.
Cancer blood tests are based on many molecular biomarkers linked to internal epithelial cancer develop-
ment. These include metabolic biomarkers, circulating cancer cells and cell-free tumour DNA11, all of which have 
associated advantages and disadvantages and thus a combination of blood-based biomarkers may have optimal 
detection capability.
One blood-based biomarker that has been assessed in OAC is lymphocyte telomere length, which appears 
to correlate with risk of disease progression12, as has the presence of the putative tumour stem cell marker 
Doublecortin Like Kinase 1 (DCLK1) in the serum of OAC patients13. Circulating tumour DNA is another 
non-invasive means of tumour surveillance, which has demonstrated promising results in early detection of 
relapse in lung cancer14. Cancer patients have higher levels of cell free circulating tumour DNA (ctDNA) in the 
blood as a result of an increase in the number or apoptotic and necrotic cells present in tumours15. Detecting 
characteristic mutations in ctDNA may allow identification of tumour origin, as well as drug resistance muta-
tions which would therefore provide an early predictor of treatment response. However, this technology is still 
in its infancy and its relevance to oesophageal malignancy is yet to be explored. A further blood-based detection 
method for malignancy is the measurement of intact circulating tumour cells, which has gained significant inter-
est with emerging technologies. Measurements such as circulating tumour cell counts may be valuable as both 
diagnostic and prognostic markers. Epethelial cell adehesion molecule (EpCAM) is the most widely used cell 
surface marker for detection and enrichment of such cells and has been used in the case of ovarian, prostate and 
colon cancer16. These tests may provide an indicator of internal neoplastic development but do not provide infor-
mation on the site or type of tumour development as is the case with the test described here in.
The advantages of developing blood-based surveillance for early OAC are clear: the ease of acquisition, lim-
itation of endoscopic complications, cost-effectiveness and ability to investigate in primary care. Targeted sur-
veillance may also allow for future patient prioritization, early diagnosis and therefore better treatment outcome.
We here present data on a potential blood-based biomarker of mutation, the erythrocyte mutation frequency 
(EMF) using Barrett’s oesophagus/oesophageal adenocarcinoma as a model form of epithelial cancer progression.
OAC is driven by acquired de novo mutations induced in the columnar metaplastic tissue, resulting from 
exposure to mutagenic chemicals such as bile and acid17,18. Therefore, as mutation underlies the progression 
of Barrett’s to cancer, blood-based mutation tests may have the potential to detect those patients with BM who 
progress to OAC. Novel DNA damage detection assays in blood cells have been successful in quantifying DNA 
mutations, in lung cancer19.
A recently developed mutation test increasingly popular in the drug safety assessment field20 was here 
evaluated to study circulating blood mutation levels in a rapid and high throughput manner. Mutations in 
the Phosphatidylinositol glycan class A (PIG-A) gene (Fig. 1) was first described in patients with the condi-
tion Paroxysmal Nocturnal Hemoglobinuria (PNH)21. The PIG-A gene encodes for a catalytic subunit of the 
N-acetylglucosamine transferase complex. This enzyme is critical in the synthesis of Glycosylphosphatidylinositol 
(GPI) anchors. GPI anchors are glycolipids which tether key proteins to the extracellular surface. A number of 
these tethered proteins, including CD55 and CD59 are important for immune response. A silencing mutation to 
the PIG-A gene results in the absence of these cellular GPI-anchors that can be indirectly measured by the lack 
of fluorescent staining. This is carried out using flow cytometry and requires the application of strictly controlled 
gating strategies.
This Pig-A gene mutation assay is now an important tool in pharma safety assessment for the evaluation 
of potential mutagens22 in rodents given its location on the X-chromosome and the possibility that one single 
mutational event can silence GPI-expression. However, it is also potentially deployable to study human mutation 
and the link between blood cell mutation level and cancer risk. Several studies of erythrocyte mutant frequency 
(EMF) levels in healthy volunteers have validated the approach and identified links to age23. Furthermore, back-
ground mutant frequencies in human erythrocytes appear to be stable (<10 mutants/million erythrocytes)23–25.
In the light of continued interest in blood-based approaches for the detection of cancer, we have evaluated 
for the first time, the potential of EMF to be deployed as a biomarker for genomic instability and thus potential 
surrogate marker of cancer using the GORD-BM-OAC model.
Results
In vitro optimization. To provide proof of principle data for this test, mutagenized L5178Y cells were 
enriched for Pig-A mutants. Enrichment using both magnetic bead separation and then flow sorting yielded 
mutant populations of 21748.22 ± 337.79 and 962842.13 ± 16846.48 mutant cells/million respectively (Fig. 2). 
The background level of mutation in the untreated L5178Y cells was 184.78 ± 70.45 mutant cells/million. The fold 
difference between technical replicates was 1.32. When grown in culture, the populations enriched for mutants 
were viable and exhibited doubling times very similar to that of the WT population. This supports the fact that 
these mutations are growth neutral, the cells viable and mutants appear not to be selected against. Further to 
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this, recent publications have proven Pig-A DNA mutation in these mutant cells by sequencing the Pig-A gene in 
similarly sorted cells26–28.
Demographic differences between participant groups. A total of 337 study participants were ana-
lyzed (Table 1), comprising 200 patients and 137 “healthy-controls”. The subject makeup included 77 patients 
with GORD, 62 with non-dysplastic Barrett’s metaplasia (NDBM), 11 with dysplasia (low or high-grade) within 
the Barrett’s segment, and 42 patients with a diagnosis of OAC. To investigate the mutagenic effects of chemother-
apeutic agents, a further 8 patients with OAC undergoing chemotherapy (CHEMO) were also included – these 
patients were receiving ECX (Epirubicin, Cisplatin and Capecitabine) therapy as per standard peri-operative 
treatment guidelines and had blood taken at various time points within their scheduled treatment. Table 1 pro-
vides further demographic information for each group.
Measuring eMF in participants. EMF was initially correlated with histological status (Fig. 3). The median 
EMF in the healthy volunteer (HV) group was 2.8 (95% CI: 2.21–3.57) mutant cells/million. In patients with 
GORD, this was noted to be 3.44 (95% CI: 1.56–5.43) mutant cells/million, non-significantly different to the HV 
group (p = 0.379). Patients with NDBM had an elevated EMF of 4.35 (95% CI: 2.49–6.09) mutant cells/million, 
significantly greater than HV’s (p = 0.036), but not greater than those with GORD (p = 0.277). Low-grade dyspla-
sia (LGD) patients had a median EMF of 5.19 (95% CI 0–14.88) mutant cells/million, not different to that of HV’s 
(p = 0.379), GORD patients (p = 0.636), patients with NDBM (p = 0.887) or OAC (p = 0.261).
Figure 1. The phosphatidylinositol glycan class A (PIG-A) gene codes for a critical step in the formation of 
glycosyl phosphatidylinositol (GPI)-Anchors. (a) Intact PIG-A gene allows for GPI-anchor synthesis and 
presentation of proteins on cell surface membrane, detectable using fluorescently tagged antibodies and flow 
cytometric methodologies. (b) Silencing Mutations to the PIG-A gene lead to absence of GPI-anchored proteins 
and non-fluorescent phenotypic mutants.
Figure 2. Mutant and wild-type phosphatidylinositol glycan class A (Pig-A) L5178Y cells. Mutant cells negative 
for the glycosyl phosphatidylinositol (GPI)-linked protein CD90.2 are indicated by arrows. (a) Untreated 
L5178Y cells. (b) L5178Y’s treated with 2 mM ethyl methanesulphonate (EMS) and enriched using anti-PE 
magnetic beads. (c) Mutagenized L5178Y cells sorted using fluorescent activated cell sorting. Insert: Image 
stream analysis of cells displaying brightfield (left) and CD90.2-PE fluorescent image (right) for Pig-A wild-type 
(top) and mutant cell (bottom).
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Interestingly, patients with high-grade dysplasia (HGD) showed elevated EMF levels as did OAC patients, with 
a median score of 7.89 (95% CI: 0–36.85) and 9.75 (95% CI: 4.36–17.52) mutant cells/million respectively. Cancer 
patients showed significantly elevated EMF compared to NDBM patients (p = 0.002), GORD patients (p < 0.001) 
and HV’s (p < 0.001). These were equivalent to approximately 3-fold (range: 3.1–3.6) increase in EMF in OAC 
compared to more benign histologies.
Chemotherapy, as expected, dramatically elevated EMF compared to other histological subsets, with a median 
mutant frequency of 62.97 (95% CI 19.71–327.07) mutant cells/million. This was significantly higher than all 
other diagnostic categories (p < 0.001 for all groups).
Visualization of GPI stained red blood cells from chemotherapy patients compared to healthy laboratory 
controls was undertaken using Imagestream® (Amnis) analysis. Clear differences in cellular fluorescence 
was observed between healthy individuals and those with a high EMF caused by the effects of chemotherapy 
(Supplementary Fig. S1). Furthermore, direct visualization of these red blood cells showed no irregularities from 
the normal biological biconcave shape. Evaluation of circularity through investigation of aspect ratio was used as 
a surrogate measure to viability and demonstrated no differences between GPI wild-type and mutant cells. Hence, 
enhanced cell death/cytotoxicity is unlikely to be a confounder for the assay.
Characteristics Healthy (n = 137) GORD (n = 77) NDBM (n = 62) LGD (n = 4) HGD (n = 7) OAC (n = 42) CHEMO (n = 8)
Age (y) (95% CI) 33 (29–40) 64 (58–66) 65 (62–69) 66.5 (50–78) 67 (62–82) 70 (66–76) 75 (65–84)
Gender, male 53% (65/137) 38% (29/77) 68% (42/62) 75% (3/4) 86% (6/7) 79% (33/42) 88% (7/8)
Hb (g/L) (95% CI) 142 (139–146) 136 (132–140) 143.5 (137–148) 140.5 (122–151) 119 (96–158) 121.5 (114–124) 123.5 (116–130)
BMI (kg/m2) (95% CI) 25.5 (24.6–26) 26.1 (25.5–27.3) 25.6 (24.8–26.4) 26.9 (24.4–29) 28 (25.1–33.2) 25 (24–25.5) 24.2 (21.5–25.2)
PPI (% use) 5% (7/137) 20% (17/77) 32% (20/62) 50% (2/4) 14% (1/7) 19% (8/42) 0% (0/8)
Aspirin (% use) 3% (4/137) 20% (15/77) 39% (24/62) 75% (3/4) 43% (3/7) 31% (13/42) 63% (5/8)
Smoking (% use) 4% (6/137) 17% (13/77) 16% (10/62) 0% (0/4) 43% (3/7) 24% (10/42) 13% (1/8)
Table 1. Demographic and lifestyle differences between the groups. Measurements recorded for each group 
included age, gender, hemoglobin levels (Hb), body mass index (BMI), proton pump inhibitor (PPI) use, 
aspirin use and smoking status. The groups included healthy volunteers and patients with gastro-oesophageal 
reflux disease (GORD), non-dysplastic Barrett’s metaplasia (NDBM), low-grade dysplasia (LGD), high-
grade dysplasia (HGD), treatment naïve oesophageal adenocarcinoma patients (OAC) and oesophageal 
adenocarcinoma patients undergoing chemotherapy treatment prior to blood sample acquisition (CHEMO). 
The median value with the 95% confidence interval (95% CI) is shown for age, Hb and BMI.
Figure 3. Erythrocyte mutation frequencies measured in different histological subsets; healthy volunteers 
(n = 137) together with patients with gastro-oesophageal reflux disease (GORD) (n = 77), non-dysplastic 
Barrett’s metaplasia (NDBM) (n = 62), low-grade dysplasia (LGD) (n = 4), high-grade dysplasia (HGD) (n = 7) 
and oesophageal adenocarcinoma who had not undergone chemotherapy (OAC) (n = 42). A significant 
increase in EMF in OAC patients compared to those with NDBM, GORD and healthy volunteers (HV)
(*p < 0.05, **p < 0.01, ***p < 0.001).
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Non-neoplastic vs HGD and cancer patients. A number of potential confounders can account for var-
iations in EMF outside of histological grade. Grouping individuals into subgroups consisting of non-neoplastic 
subjects (Healthy Volunteers, GORD patients and those with non-dysplastic Barrett’s metaplasia) and those with 
HGD and adenocarcinoma allowed for a more powerful evaluation, as shown in Supplementary Table S1. LGD 
(n = 4) which in itself is thought to encompass a spectrum of disease and as such is often misdiagnosed was omit-
ted from this analysis. Univariate analysis showed HGD and cancer patients are nearly always male (79.6%), and 
older (median age 70 years (95% CI 66–75)) compared to the non-neoplastic group, 53 years (95% CI 51–55), 
(p < 0.001). Furthermore, these patients were more anemic than the non-neoplastic counterparts, (p < 0.001).
Average EMF was significantly higher in the HGD and cancer group and was associated with more advanced 
histological stage (p < 0.001). Accounting for all variables, using a multivariate analysis a higher EMF is a risk for 
more advanced histological stage, (p = 0.006). Analysing EMF alone, a cut-off score of 5.31 mutant cells/million 
gives a sensitivity of 61% and specificity of 68% with an Area under the receiver operating characteristic curve 
of 0.715. However, a multivariate analysis reveals predictors of falling within the HGD and cancer group include 
older age, male gender, high BMI, low haemoglobin and high EMF. A logistic regression was performed using 
these variables to predict risk, giving a sensitivity of 57.1% but improving specificity to 97.1% with a positive pre-
dictive value of 77.8% and negative predictive value of 92.7%.
tumour staging and eMF. Within the OAC patients, higher EMF was associated with more advanced 
tumour staging (p = 0.014). This was broken down into TNM score where T is a measure of size of the origi-
nal tumour, N indicates lymph node involvement and M indicates the metastatic status of the tumour. Higher 
EMF was associated with more lymph node involvement (N score) (p = 0.019) and metastatic disease (p = 0.008), 
although no association with EMF and T-score was observed (p = 0.627) as shown in Fig. 4.
Lifestyle and medication effects on EMF. Within the non-neoplastic group, we interrogated possible 
factors that may have an influence on the assay. There was a small positive correlation between increasing age an 
elevated EMF, (Rho = 0.229, p < 0.001). Gender was not associated with any statistically significant differences 
in EMF. Higher BMI was also associated with a statistically significant EMF increase, (Rho = 0.131, p = 0.03). 
Smokers (n = 29) had more than double an increase in median mutant frequency compared with non-smokers 
(n = 247) with an EMF of 5.82 (95% CI 2.79–9.52) and 2.8 (95% CI 2.49–3.57) mutant cells/million respectively 
(p = 0.011). Interestingly aspirin use was also associated with a protective lower EMF in those taking it (n = 43) 
compared to those not (n = 233) (p = 0.001), with EMF values of 1.51 (95% CI 0–2.49) and 3.57 (95% CI 2.8–
4.17) mutant cells/million respectively. Finally, proton pump inhibitor (PPI) use increased EMF to 4.68 (95% CI 
Figure 4. Erythrocyte mutant frequency (EMF) scores for different tumour staging further broken down into 
aspects of Tumour Node Metastasis (TNM) scoring. Statistically determined outliers are represented with their 
corresponding participant ID as either a circle or asterix. The number of patients in each staging subgroup is 
provided below. (a) Significant increase in EMF with increasing tumour staging (p = 0.014). TI (n = 5), TII 
(n = 19), TIII (n = 12) and TIV (n = 6). (b) No difference in EMF between different primary tumour sizes 
(T-score) (p = 0.627). T1a (n = 3), T1b (n = 8), T2 (n = 16), T3 (n = 12) and T4a (n = 3). (c) A significant 
increase in EMF with more lymph node involvement (N-score). (p = 0.019). N0 (n = 15), N1 (n = 14), N2 
(n = 11) and N3 (n = 2). (d) Higher EMF significantly associated with metastatic disease (M-score)(p = 0.008). 
M0 (n = 36) and M1 (n = 6).
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2.74–6.42) mutant cells/million compared to those not on regular acid suppression, who had a median EMF 2.82 
(95% CI 2.3–3.51) mutant cells/million (p = 0.012).
Discussion
OAC has one of the worst prognoses of all cancers due to the lateness with which patients present with symptoms. 
BM, the only known precursor to OAC, serves as a potentially important histological point at which patients can 
be risk stratified. However, identification of BM patients remains suboptimal as many asymptomatic patients 
present with OAC, therefore new approaches are urgently needed to detect this cancer at an early, treatable stage.
The importance of blood-based approaches in the diagnosis of cancers has gained significant attention of late 
with the identification of abnormalities in circulating proteins, metabolites and cell free DNA29,30. Here we eval-
uated a novel, surrogate blood-based biomarker for use in patient stratification. The PIG-A gene mutation assay 
is an indirect assessment of mutation, through the identification of the presence or absence of GPI-anchored 
proteins in erythrocytes.
Significantly higher EMF’s were observed in OAC patients than HV’s or GORD patients (3 fold overall). 
However, some cancer patients had EMF’s equivalent to the non-cancer cohort, with this approach having a 
sensitivity of 63% for detection of OAC patients. Although this figure appears modest, it can be compared to the 
current blood-based biomarker used in clinic for prostate cancer; prostate specific antigen (PSA) testing. Using a 
cut-off value of 4.0 ng/ml of serum PSA provides a sensitivity of only 21% for malignancy and 51% for high-grade 
cancers (Gleason score > 8)31. Furthermore, if over 60% of the 9,211 cases of OAC diagnosed annually in the 
UK32 were detected earlier, improving the prognosis for over 5 800 patients, such testing could have a significant 
impact on patient mortality. It is interesting that high EMF’s were noted in a minority of patients with GORD and 
NDBM. Close follow up of these individuals will allow association of any accelerated neoplastic development in 
these patients over the coming years.
The fact that there was elevation of EMF’s in many cancer patients could have multiple potential explanations. 
Whilst mutations to the PIG-A gene have not been identified as a causative risk factor for OAC, and patients with 
the underlying PNH condition are not at more risk of these cancers compared to their normal counterparts, it is 
plausible that the detection of higher circulating GPI-anchor deficient erythrocytes in patients with cancer could 
be a measure of an underlying susceptibility to mutation. Given that heterogeneity and genomic instability within 
the Barrett’s segment is associated with increased risk of progression to adenocarcinoma33, the observations of 
higher mutant frequencies in high-risk groups is not surprising.
Furthermore, higher EMF was associated with worse tumour staging and when broken down in to TNM 
score, higher EMF was associated with more lymph node involvement and metastatic disease. This is perhaps 
explained by the idea that tumours must acquire more mutations in key metastatic genes such as E-cadherin if 
they are to invade distally34. Although no significant differences were found in EMF between T-scores, this may 
be due to the limited numbers of patients currently falling into each T-score category.
Interestingly, there was a small positive correlation between EMF and age perhaps due to the fact that spon-
taneous somatic mutations are associated with cell divisions and hence age35. A small correlation between 
BMI and EMF was observed; perhaps not surprising considering obesity is a major risk factor for many malig-
nancies including OAC. Further to this, a recent study found elevated levels of erythrocyte Pig-A mutation in 
diet-induced obese mice, compared to their healthy counterparts36. Moreover, with the known carcinogenic 
effects of cigarette smoking, it is fascinating to note that we found a significant increase in EMF in smokers 
compared to non-smokers. This is supported by evidence from both the rodent37 and in vitro assay27 where ben-
zo[a]pyrene, a compound found in cigarettes, induced Pig-A mutation. With a large amount of research efforts 
focused on exploring the protective effects of aspirin against OAC, the fact that aspirin users had lower EMF’s 
than non-aspirin users is significant. This is supported by the recent AspECT clinical trial which found aspirin 
intake may have chemopreventative effects in Barrett’s patients38. The increase in EMF’s in participants who were 
prescribed PPI medication is surprising. Although the reason behind this is unclear and warrants further investi-
gation, it is perhaps associated with symptom severity.
The mechanism underpinning the origin of PIG-A mutants remains unclear and warrants further investiga-
tion. Mutagenic chemicals in the distal oesophagus such as bile and acid can induce mutation through induc-
tion of pro-inflammatory transcription factors such as NF-kB39, leading to immune cell driven DNA damage40. 
Alternatively, soluble mutagenic and/or inflammatory factors secreted into the blood may expose the bone mar-
row compartment to noxious agents leading to in situ mutational events in stem cells which are subsequently 
passed on to the daughter blood cell pool.
We observed a significant increase in the mutant frequency of erythrocytes in patients undergoing chemother-
apy for OAC. This is likely to be a manifestation of the mutagenic effects of chemotherapy at a bone marrow level. 
Although blood was drawn from these patients at only one time point during their treatment, these patients rep-
resent a positive control group for a mutation assay, such as PIG-A. Given some patients yielded a larger mutant 
response to chemotherapy than others, this suggests that some individuals may be more susceptible to mutation 
than others and that this approach could have utility in monitoring response to chemotherapy. However, as the 
time taken for mutant cell manifestation post mutagenic exposure is currently unknown, further work is required 
to measure PIG-A mutation pre and post treatment to identify possible chemotherapy induced mutations.
We appreciate the limitations to this work, specifically, the variation in baseline demographic data between 
the different histological groups recruited. However, we understand this accurately reflects the relative rarity of 
oesophageal adenocarcinoma as well as the obvious age and gender preponderance that exists in oesophageal ade-
nocarcinoma diagnoses. We acknowledge the limited sample sizes in some groups, for example in the LGD and 
HGD groups as well as in some of the tumour staging subgroups. However, this is sometimes the nature of pilot 
data and increasing sample sizes as well as carrying out longitudinal type studies may provide further clarification 
on the usefulness of this surrogate predictor of malignancy.
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It is important to consider the potential effects of complement mediated lysis on PIG-A mutant cells as many 
GPI-linked proteins such as CD55 and CD59 protect the cell against complement mediated attack. Notably, the 
symptoms of PNH, such as blood in the urine are a result of a vast amount of complement mediated erythroly-
sis21. However, it is possible that when mutant cells are at such a low prevalence in circulation (as is the case in the 
population studied here), it is perhaps not sufficient to induce the complement cascade of events leading to eryth-
rolysis. Furthermore, studies have measured the potential effects of complement on GPI-negative erythrocytes 
in rodents by measuring mutant cell frequency in immature red cells; reticulocytes, and mature erythrocytes. 
Although some studies have demonstrated that reticulocytes may be a better option to measure mutation post 
mutagenic exposure (in genotoxicology safety assessment)41, importantly, background levels of PIG-A mutant 
cells have been similar between both cell types42, suggesting the relatively minor role, if any, complement plays in 
detecting and destroying mutant cells when in such low abundance.
It would be preferable to link mutant cells to sequencing data to verify mutation in a similar manner to that 
already demonstrated in the assay in rodent splenic T-cells43 and in vitro mouse lymphoma cells26–28. This is 
impossible through the use of anuclear erythrocytes and whilst upstream nucleated cells could yield information 
regarding mutational events to the PIG-A gene, the low abundance of these cells make them more difficult to 
analyze.
It is important to note however that, there are several advantages to this particular surrogate biomarker. Data 
can be quickly acquired, collected non-invasively and the methodology harnesses the power of flow cytometry in 
detecting extremely rare events, allowing for such low background mutant frequencies to be detected that subtle 
variations of this will be easily seen. Moreover, given that the test uses only 10 μl of blood, it would be amenable to 
utilizing finger prick testing instead of venipuncture allowing for an even less invasive approach.
A large amount of research effort has recently focused on “liquid biopsy” biomarkers including measuring 
cell free circulating tumour DNA and tumour cells in the blood. Although sequencing certain oncogenes such as 
KRAS in cell free DNA has proven useful in pancreatic44 and colorectal cancer45, detection methods remain poor 
and although improving, sequencing costs are still relatively expensive for widespread clinical roll-out. Moreover, 
spectroscopic methods such as nuclear magnetic resonance (NMR) profiling have recently been applied as a diag-
nostic tool for OAC, allowing for the discrimination of OAC patients compared to controls based on the measure-
ment of altered metabolites such as sucrose and urea in patient urine. A difference between BM and OAC was also 
distinguishable with this NMR approach46. Such measurements not only allow for less invasive diagnosis but may 
provide further information on tumour metabolism and are perhaps most useful when used in combination with 
other biomarkers. In reality, a battery of non-invasive tests may provide the most useful, measuring a combination 
of different end-points, further improving sensitivity and specificity.
Whilst further validation of the work should be performed to better establish biological and specific lifestyle 
confounders, this pilot EMF data does show promise to be investigated as a secondary biomarker in the investi-
gation of patients with GORD and BM.
In conclusion, this proof-of-principle study has shown that the PIG-A gene mutation assay has some potential 
use as a surrogate marker for oesophageal malignancy by detecting subtle changes in EMF. Given the need for 
better systems to guide current surveillance strategies in BM, this assay could complement existing biomarkers 
as a means of a cheap, reproducible and well-tolerated investigation for patients with GORD and BM. It may also 
have the potential to be used in other cancer models as well as in the monitoring of response to chemotherapy.
patients and Methods
Ethical approval was granted by the South West Wales local research ethics committee (11/WA/0367) and 
sponsorship was obtained from Abertawe Bro Morgannwg University Health Board (in full) Research and 
Development department. All patients gave full informed consent and were recruited through the Department 
of Endoscopy, Singleton Hospital, Swansea (UK), between 1st June 2013 and the 26thJuly 2018. All experiments 
carried out adhered to relevant guidelines and regulations. Patients with GORD were identified before attendance 
from primary care referrals. A gastro-esophageal reflux disease questionnaire (GERDQ) score47 was used before-
hand to detect true reflux disease with a cutoff score > 8 used. All GORD patients were confirmed BM negative 
upon endoscopy. Patients with a GERDQ score < 8 whose endoscopy reported no oesophagitis were included 
in the healthy volunteer cohort (n = 15). Patients with BM were recruited during attendance at 2-yearly surveil-
lance endoscopy who had previous histology report confirming the presence of BM. Dysplastic BM patients were 
enrolled during endoscopy prior to ablation, whilst OAC patients were recruited from known cancers presenting 
for stenting, or new patients presenting with dysphagia. A modified European prospective investigation into 
cancer and nutrition (EPIC)48 questionnaire was completed in the waiting room by all patients. A dietary quality 
score (DQS) and health promotion index (HPI) score was calculated for each patient based on their submitted 
questionnaire. Chemotherapy patients receiving standard epirubicin, cisplatin and capecitabine (ECX) treatment 
were also recruited. Blood was obtained from these patients at varying time points post treatment. Patient EMF’s 
were compared to a parallel collection of healthy volunteers (collected from University staff and students under 
South West Wales Local ethical committee approval 13/WA/0190). These healthy volunteers (n = 122) did not 
undergo endoscopy although 3 participants were taking prescribed PPI medication at the time of blood sample 
acquisition.
Methods
Optimization and validation of the EMF biomarker was undertaken in-vitro using the mouse lymphoma cell 
line L5178Y Tk+/−. Cells were grown in culture as previously described26. To induce mutation, cells were dosed 
with 2 mM ethylmethane sulphonate (EMS) for 4 hours. After a 21-day mutant expression period, cells were 
magnetically enriched for Pig-A mutant cells using anti-PE microbeads (Miltenyi biotec, Bergish Gladbach, 
Germany). Twenty-eight days after dosing, cells underwent fluorescent activated cell sorting (BD Facs Aria III 
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(BD biosciences, Franklin Lakes, New Jersey, USA) in order to enrich the mutant population further. Cells were 
stained with zombie violet viability dye at room temperature for 30 minutes followed by staining with an antibody 
solution containing 0.18μg anti-CD45 APC; to exclude non-specific events and anti-CD90.2 PE; a GPI-linked 
protein (Biolegend, San Diego, California, USA).
To ensure further optimization, particularly in regard to gating strategy and reproducibility, studies with 
healthy volunteer blood samples assessed antibody concentration, incubation time and flow cytometric parame-
ters to optimize the methodology (data not shown).
In the clinical study, prior to endoscopy, blood was acquired for EMF analysis into a heparinised blood collec-
tion tube (BD biosciences). All blood samples were coded at the point of acquisition to both blind the study and 
maintain patient anonymity. All patient samples were analysed within 24 hours of blood collection.
Ten microlitres of whole blood was required for PIG-A analysis. This was incubated with 5 μl of a 1:10 dilu-
tion of anti-CD235a APC (BD Biosciences) for erythrocyte analysis (0.1 μl/106 cells). Twenty microlitres of both 
anti-CD55 PE and anti-CD59 PE antibodies (BD Biosciences) were used for PIG-A analysis (0.4 μl/106 cells). 
Samples were incubated in the dark for 30-minutes. Fluorophores were selected so that spectral overlap would 
not confound assessment.
Following removal of the supernatant antibody cocktail, two wash steps incorporating centrifugation for 
5 minutes at 500 G followed by resuspension in 2% Bovine Serum Albumin (BSA) in Phosphate Buffered Saline 
(PBS) (Sigma, St Louis, Missouri, USA) were carried out. The pellet was finally resuspended in 1 ml of 2% BSA/
PBS solution and kept in the dark prior to analysis.
Flow cytometry was undertaken on both a BD FACS Aria I cell-sorter and Beckman Coulter Navios (Beckman 
Coulter, Brea, California, USA). These both utilized 488 nm blue and 633 nm red lasers with default filters.
A subset of 122 samples (from both healthy volunteers and patients) was run on both flow cytometers 
(Supplementary Fig. S2). There was a strong correlation between the two machines (rho = 0.527, p < 0.001) allow-
ing for normalization between the two systems. This was carried out using the correlation line of best fit.
Unstained control samples of each patient were crucially used as an Instrument Calibration Standard (ICS). 
A robust mutant gate (Fig. 5) was thus drawn from this ICS sample so that >90% of the unstained population 
lay within it. This ensured an objective assessment of “mutant” phenotype for each participant. All participant 
samples were independently stained 3-times in parallel to provide triplicate data and 1 million wild type events 
Figure 5. Gating Strategies employed for erythrocyte mutant frequency (EMF) analysis. (a) Erythrocytes 
initially identified by their forward scatter and side scatter profiles. (b) CD235a staining is used to characterize 
red blood cells and exclude other cell populations. (c) Single cells can be identified separate to clumped cells 
and gated for subsequent analysis. (d) A gate is drawn from an instrument calibration standard (ICS) to enable 
isolation of mutant (negatively fluorescent) cells. (e) Analysis of double stained samples reveal positively stained 
wild type red blood cells, and negative mutant populations. (f) Gating can be performed using cytograms and 
images viewed using the imagestream (Amnis) to confirm fluorescent status and cell morphology.
9Scientific RepoRts |          (2019) 9:5168  | https://doi.org/10.1038/s41598-019-41490-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
were counted for each replicate in order to express mutant frequency as number of events/million. The average 
variation between technical replicates was 48.28%.
Image stream analysis was additionally undertaken during optimization on both patient erythrocytes and 
L5178Y cells to visually verify changes in fluorescence between samples as well as to crucially assess the viability 
of cells. Samples were prepared as above and run on the Imagestream X (Amnis, Seattle, Washington, USA), and 
10,000 events were collected.
Flow cytometry data and Imagestream data collected were interpreted using BD FACS Diva 8.0 (BD 
Biosciences), FlowJo v10 (FlowJo, Ashland, Oregon, USA) and Image Data Exploration and Analysis Software 
(IDEAS) v4.0 (Amnis) respectively.
EMF was analyzed against histological stage. Two expert pathologists corroborated all histological diagnoses. 
Histological stage was confirmed at time of blood sample acquisition unless a more advanced histological stage 
was confirmed at a later date.
statistical analysis. As the PIG-A gene mutation assay is a completely novel test to be investigated as a 
biomarker in the Barrett’s model, this study was effectively a pilot investigation and no power calculations could 
be calculated to guide recruitment. Mean EMF’s were recorded from the triplicate data obtained from each indi-
vidual. Normality was assessed using the one-sample Kolmogorov-Smirnov Goodness of Fit test. Median EMF 
values together with the corresponding 95% confidence intervals are reported for each category. Multivariable 
analysis of EMF and confounding lifestyle and dietary variables was undertaken using binary logistic regression. 
A General Linear Model was constructed to identify risk factors for development of cancer and statistical signifi-
cance was set as p < 0.05. The sensitivity and specificity of the assay was calculated using an ROC curve. Statistical 
calculations were performed using the Statistical Package for the Social Sciences (SPSS 23.0, IBM Corp., Armonk, 
New York, USA).
ethics approval and consent to participate. Ethical approval was granted by the South West Wales 
local research ethics committee (11/WA/0367) and sponsorship was obtained from ABMU (in full) Research and 
Development department. The healthy volunteer recruitment was carried out under ethical approval 13/WA0190 
granted by South West Wales Local ethic committee. All patients and healthy volunteers provided informed con-
sent to participate in the corresponding studies.
Data Availability
Data will be made available to other researchers post publication upon reasonable request to the corresponding 
author. Information on individual patients/participants will not be made available.
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